Rituximab in combination with CODOX-M/IVAC: A retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%

British Journal of Haematology

Volumn 152, Issue 2, 2011, Pages 175-181

  Mohamedbhai, Sajir G ^a   Sibson, Keith ^a   Marafioti, Teresa ^a   Kayani, Irfan ^a   Lowry, Lisa ^b   Goldstone, Anthony H ^a   Linch, David C ^a,b   Ardeshna, Kirit M ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Burkitt lymphoma; CODOX M IVAC; Diffuse large B cell lymphoma; PET CT scan; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LARGE CELL LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEPSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 78650317141     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08447.x     Document Type: Article

References (16)

1. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
2. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235-242.
3. Dunleavy, K., Healey Bird, B.R., Pittaluga, S., Grant, N., Shovlin, M., Little, R., Yarchoan, R., Steinberg, S., Jaffe, E.S., Janik, J. & Wilson, W.H. (2007) Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt lymphoma. Journal of Clinical Oncology (ASCO Annual Meeting Proceedings Part I), 25, 8035.
4. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France.
5. Johnson, N.A., Boyle, M., Bashashati, A., Leach, S., Brooks-Wilson, A., Sehn, L.H., Chhanabhai, M., Brinkman, R.R., Connors, J.M., Weng, A.P. & Gascoyne, R.D. (2009) Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. Blood, 113, 3773-3780.
6. Karantanis, D., Durski, J.M., Lowe, V.J., Nathan, M.A., Mullan, B.P., Georgiou, E., Johnston, P.B. & Wiseman, G.A. (2009) 18F-FDG PET and PET-CT in Burkitt's lymphoma. European Journal of Radiology, 75, e68-e73.
7. Kasamon, Y.L. & Wahl, R.L. (2008) FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Current Opinion in Oncology, 20, 206-219.
8. Magrath, I., Adde, M., Shad, A., Venzon, D., Seibel, N., Gootenberg, J., Neely, J., Arndt, C., Nieder, M., Jaffe, E., Wittes, R.A. & Horak, I.D. (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925-934.
9. Hummel, M., Bentink, S., Berger, H., Klapper, W., Wessendorf, S., Barth, T.F.E., Bernd, H-W., Cogliatti, S.B., Dierlamm, J., Feller, A.C., Hansmann, M-L., Haralambieva, E., Harder, L., Hasenclever, D., Kühn, M., Lenze, D., Lichter, P., Martin-Subero, J.I., Möller, P., Müller-Hermelink, H-K., Ott, G., Parwaresch, R.M., Pott, C., Rosenwald, A., Rosolowski, M., Schwaenen, C., Stürzenhofecker, B., Szczepanowski, M., Trautmann, H., Wacker, H-H., Spang, R., Loeffler, M., Trümper, L., Stein, H., & Siebert, R. for the Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New England Journal of Medicine, 354, 2419-2430.
10. Mead, G.M., Sydes, M.R., Walewski, J., Grigg, A., Hatton, C.S., Pescosta, N., Guarnaccia, C., Lewis, M.S., McKendrick, J., Stenning, S.P. & Wright, D. (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264-1274.
11. Mead, G.M., Barrans, S.L., Qian, W., Walewski, J., Radford, J.A., Wolf, M., Clawson, S.M., Stenning, S.P., Yule, C.L. & Jack, A.S. (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood, 112, 2248-2260.
12. Pfreundschuh, M., Trümper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P.L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., López-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E. & Loeffler, M. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology, 7, 379-391.
13. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A. & Stein, H. (2008) WHO Classification of Tumours of Haematological and Lymphoid Tissues. WHO Press, Lyon France.
14. Thomas, D.A., Faderl, S., O'Brien, S., Bueso-Ramos, C., Cortes, J., Garcia-Manero, G., Giles, F.J., Verstovsek, S., Wierda, W.G., Pierce, S.A., Shan, J., Brandt, M., Hagemeister, F.B., Keating, M.J., Cabanillas, F. & Kantarjian, H. (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 106, 1569-1580.
15. WHO (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva.
16. Yokohama, A., Tsukamoto, N., Uchiumi, H., Handa, H., Matsushima, T., Karasawa, M., Murakami, H. & Nojima, Y. (2004) Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt's lymphoma. Annals of Haematology, 83, 120-123.